Initial Results in a Phase 1b Trial of PB-04 in Sickle Cell Disease Demonstrate Fetal Hemoglobin Induction, Additive Activity with Hydroxyurea, and Improved Red Blood Cell Sickling ParametersKevin H.M. Kuo, Susan P. Perrine, Sylvia T. Singer et al.|Blood|2023Cited by 2
PP-14, a Novel Structurally-Enhanced Antisickling Allosteric Hemoglobin Effector, Increases Oxygen Affinity and Disrupts Hemoglobin S Polymer FormationMartin K. Safo, Osheiza Abdulmalik, Xiaomeng Xu et al.|Blood|2019Cited by 1
PB-04 Induces HbF Expression in a Ph1b Trial in Sickle Cell DiseaseSusan P. Perrine, Patrick C. Hines, Lanetta Bronté-Hall et al.|Journal of sickle cell disease.|2024Cited by 1